References
- Abdelbary G. (2011). Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes. Pharm Dev Technol 16:44–56.
- Abdelkader H, Longman MR, Alany RG, Pierscionek B. (2016). Phytosome-hyaluronic acid systems for ocular delivery of L-carnosine. Int J Nanomed 11:2815–27.
- Altamirano-Vallejo JC, Navarro-Partida J, Gonzalez-De lRA, et al. (2018). Characterization and pharmacokinetics of triamcinolone acetonide-loaded liposomes topical formulations for vitreoretinal drug delivery. J Ocul Pharm Ther. jop.2017.0099.
- Bahrami B, Zhu M, Hong T, Chang A. (2016). Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia 59:1594–608.
- Bourlais CL, Acar L, Zia H, et al. (1998). Ophthalmic drug delivery systems-recent advances. Prog Retin Eye Res 17:33–58.
- Chang-Lin JE, Attar M, Acheampong AA, et al. (2011). Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 52:80–6.
- Cho IS, Park CG, Huh BK, et al. (2016). Thermosensitive hexanoyl glycol chitosan-based ocular delivery system for glaucoma therapy. Acta Biomater 39:124–32.
- Daruich A, Matet A, Moulin A, et al. (2017). Mechanisms of macular edema: Beyond the surface. Prog Retinal Eye Res 63:20–68.
- Ebrahim S, Peyman GA, Lee PJ. (2005). Applications of liposomes in ophthalmology. Sur Ophthalmol 50:167–82.
- Fuente MDL, Raviña M, Paolicelli P, et al. (2010). Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev 62:100–17.
- Herrero-Vanrell R, Cardillo JA, Kuppermann BD. (2011). Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clinical Ophthalmology 5:139–46.
- Hironaka K, Inokuchi Y, Fujisawa T, et al. (2011). Edaravone-loaded liposomes for retinal protection against oxidative stress-induced retinal damage. Eur J Pharm Biopharm 79:119–25.
- Hironaka K, Inokuchi Y, Tozuka Y, et al. (2009). Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J Control Rel 136:247–53.
- Knudsen KB, Northeved H, Pramod Kumar EK, et al. (2015). In vivo toxicity of cationic micelles and liposomes. Nanomed Nanotechnol Biol Med 11:467–77.
- Ludwig A. (2005). The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 57:1595–639.
- Reid GA, Sahota DS, Sarhan M. (2015). Observed complications from dexamethasone intravitreal implant for the treatment of macular edema in retinal vein occlusion over 3 treatment rounds. Retina 35:1647–55.
- Rohatagi S, Hochhaus G, Mollmann H, et al. (1995). Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 35:1187–93.
- Ruponen M, Urtti A. (2015). Undefined role of mucus as a barrier in ocular drug delivery. Eur J Pharm Biopharm 96:442.
- Shikari H, Silva PS, Sun JK. (2014). Complications of intravitreal injections in patients with diabetes. Sem Ophthalmol 29:276–89.
- Tan G, Yu S, Pan H, et al. (2017). Bioadhesive chitosan-loaded liposomes: a more efficient and higher permeable ocular delivery platform for timolol maleate. Int J Biol Macromol 94:355.
- Tian BC, Zhang WJ, Xu HM, et al. (2013). Further investigation of nanostructured lipid carriers as an ocular delivery system: in vivo transcorneal mechanism and in vitro release study. Coll Surf B Biointer 102:251–6.